ALSUntangled 59: Tamoxifen: The Alsuntangled Group. Issue 7 (2nd October 2021)

• Record Type: Journal Article
• Authors: Bedlack, Richard; Kihuwa-mani, Sky; Barkhaus, Paul E.; Bereman, Michael; Caress, James B.; Crayle, Jesse; Pattee, Gary L.; Heiman Patterson, Terry; Wicks, Paul; Zach, Neta; Carter, Gregory T.; Salmon, Kristiana
• Is Part Of: Amyotrophic lateral sclerosis and frontotemporal degeneration. Volume 22:Issue 7/8(2021)
• Page Start: 595
• Page End: 598
• Publication Date: 2021-10-02
• Subjects: Tamoxifen -- ALSUntangled -- off-label treatment -- trials -- ethics -- therapy -- clinical trials; 616.839
• DOI: 10.1080/21678421.2021.1876731
• Languages: English
• ISSNs: 2167-8421

Abstract

Abstract: Here we use the ALSUntangled methodology to review Tamoxifen as an ALS treatment. We show that it has plausible mechanisms, a positive preclinical study, a case report and 2 small trials suggesting benefits. We show that it appears reasonably safe, though there is a small risk of developing cancer with long term use. While we cannot yet endorse this as an ALS treatment, there is enough evidence to warrant another larger ALS trial.